Japan · 費用対効果評価 · C2H · Chuikyo · NHI price adjustment
Every product Japan has designated for cost-effectiveness evaluation since 2019: class, dates, the ICER category Chuikyo approved and how much the NHI price moved — plus which products are next. Compiled from C2H (National Institute of Public Health) and Chuikyo (MHLW) documents; processed by the editor. Not an official translation.
Data as of 2026-09-29 · sources: C2H (NIPH), MHLW Chuikyo (PDL1.0); processed by Japan Pharma Regulatory Brief · CSV (aggregates) · 한국어 요약
| FY2019 | 6 |
| FY2020 | 8 |
| FY2021 | 15 |
| FY2022 | 13 |
| FY2023 | 8 |
| FY2024 | 13 |
| FY2025 | 10 |
| FY2026 | 10 |
| H1 — peak sales forecast ≥ ¥10bn | 56 |
| H2 — ¥5–10bn (Chuikyo selects) | 11 |
| H3 — notably high price / new evidence | 2 |
| H5 — similar product, follows its lead | 14 |
H4 has never been used.
| Completed | 50 |
| In progress | 20 |
| H5 (follows lead product) | 12 |
| Analysis suspended | 1 |
From designation to the Chuikyo general assembly approving the result: median 556.5 days (about 18 months; interquartile range 532–605.5 days, fastest 427, slowest 1204, n=50 H1–H4 products). That is longer than the official 15–18 month guide. The adjusted price then takes effect at the next quarterly window, usually 2–4 months later.
% change of the NHI price at the HTA price adjustment, first listed strength, including H5 similar products (n=57): median -4.08%, interquartile range -7.75% to -0.46%. Among H1–H4 products that were cut, the median is -4.29% (n=38).
MHLW’s own figure (2025-09 (Chuikyo HTA subcommittee; restated 2026-09-09 費-1)): 38 of 49 completed evaluations had a price change, median -4.29% of the whole price (PDF). Measured slightly differently from ours; comparable, not identical.
| increase (>0%) | 0 |
| no change (0%) | 12 |
| 0 to -5% | 24 |
| -5 to -10% | 15 |
| -10 to -15% | 6 |
| below -15% | 0 |
Newest designation first; click a column to sort. ICER category = the band approved by Chuikyo for each analysed population (healthcare payer view). Price adjustment = first listed strength (range shown when strengths differ). Days are counted to the Chuikyo result, not shown for H5 products. * = figures read from the Japanese PDFs by machine and not yet checked by hand (65 of 83 rows); 18 rows are hand-checked.
| Product | Ingredient | Company | Class | Designated | Chuikyo result | Days | ICER category (healthcare payer view) | Price adjustment | Effective | C2H |
|---|---|---|---|---|---|---|---|---|---|---|
| SARCLISA* サークリサ | Isatuximab | H1 In progress | 2026-08-05 | not yet | C2H2610 list only | |||||
| MERCILON* マルシロン | Desogestrel, ethinylestradiol | H2 In progress | 2026-08-05 | not yet | C2H2609 list only | |||||
| Cobalt XT HF Quad CRT-D MRI* device Cobalt XT HF Quad CRT-D MRI | Cardiac resynchronization therapy defibrillator | H2 In progress | 2026-07-22 | not yet | C2H2608 list only | |||||
| Cobalt XT DR MRI* device Cobalt XT DR MRI | Implantable cardioverter defibrillator | H2 In progress | 2026-07-22 | not yet | C2H2607 list only | |||||
| SAPIEN 3 Ultra RESILIA systetm* device エドワーズ サピエン3 Ultra RESILIA システム | Transcatheter heart valve | H1 In progress | 2026-07-22 | not yet | C2H2606 list only | |||||
| ADSTILADRIN* エドスチラドリン | nadofaragene firadenovec | H1 In progress | 2026-07-08 | not yet | C2H2605 list only | |||||
| JASCAYD* ジャスケイド | Nerandomilast | H1 In progress | 2026-07-08 | not yet | C2H2604 list only | |||||
| Zolgensma IT* ゾルゲンスマ髄注 | Onasemnogene abeparvovec | H5 In progress | 2026-05-13 | follows lead product | not yet | C2H2603 list only | ||||
| EXDENSUR* エキシデンサー | Depemokimab | H1 In progress | 2026-04-08 | not yet | C2H2602 list only | |||||
| AQUIPTA* アクイプタ | Atogepant hydrate | H5 In progress | 2026-04-08 | follows lead product | not yet | C2H2601 | ||||
| BLENREP* ブーレンレップ | Belantamab mafodotin | H1 In progress | 2026-03-11 | not yet | C2H2510 list only | |||||
| PLUVICTO* プルヴィクト | Lutetium (177Lu) vipivotide tetraxetan | H1 In progress | 2025-11-05 | not yet | C2H2509 list only | |||||
| IZERVAY* アイザベイ | Avacincaptad pegol sodium | H1 In progress | 2025-11-05 | not yet | C2H2508 list only | |||||
| NEXLETOL* ネクセトール | Bempedoic acid | H1 In progress | 2025-11-05 | not yet | C2H2507 list only | |||||
| Nurtec* ナルティーク | Rimegepant sulfate hydrate | H1 In progress | 2025-11-05 | not yet | C2H2506 list only | |||||
| YORVIPATH* ヨビパス | Palopegteriparatide | H1 In progress | 2025-10-15 | not yet | C2H2505 list only | |||||
| TALVEY* タービー | Talquetamab | H1 In progress | 2025-08-06 | not yet | C2H2504 list only | |||||
| AIRWIN* エアウィン | Sotatercept | H1 In progress | 2025-08-06 | not yet | C2H2503 list only | |||||
| WELIREG* ウェリレグ | Belzutifan | H1 In progress | 2025-08-06 | not yet | C2H2502 list only | |||||
| IMDELLTRA* イムデトラ | Tarlatamab | H1 In progress | 2025-04-09 | not yet | C2H2501 | |||||
| LUNSUMIO* ルンスミオ | Mosunetuzumab | Chugai Pharmaceutical Co., Ltd. | H5 H5 (follows lead product) | 2025-03-12 | follows lead product | -2.73% H5 of C2H2307 | 2025-08-01 | C2H2413 list only | ||
| TECVAYLI* テクベイリ | Teclistamab | (株) | H5 H5 (follows lead product) | 2025-03-12 | follows lead product | 0% H5 of C2H2403 | C2H2412 list only | |||
| DATROWAY* ダトロウェイ | Datopotamab deruxtecan | (株) | H5 H5 (follows lead product) | 2025-03-12 | follows lead product | -11.00% H5 of C2H2409 | 2026-11-01 | C2H2411 list only | ||
| Zepbound ゼップバウンド | Tirzepatide | Eli Lilly Japan K.K. | H1 Completed | 2025-03-12 | 2026-08-26 | 532 | <2M yen/QALY | pending | C2H2410 | |
| TRODELVY トロデルビ | Sacituzumab govitecan | Gilead Sciences K.K. | H2 Completed | 2024-11-13 | 2026-05-13 | 546 | ≥15M yen/QALY | -11.00% | 2026-11-01 | C2H2409 |
| Awiqli アウィクリ | Insulin icodec | Novo Nordisk Pharma Ltd. | H1 Completed | 2024-11-13 | 2026-06-24 | 588 | Cost increase (no added benefit); Equivalent effect and cost | -0.34% -0.42 to -0.34% | 2026-11-01 | C2H2408 |
| TEPEZZA テッペーザ | Teprotumumab | Amgen K.K. | H1 Completed | 2024-11-13 | 2026-05-13 | 546 | 7.5M–10M yen/QALY | -5.51% | 2026-11-01 | C2H2407 |
| Kisunla ケサンラ | Donanemab | Eli Lilly Japan K.K. | H1 Completed | 2024-11-13 | 2026-08-26 | 651 | Cost-saving (dominant); ≥10M yen/QALY | pending | C2H2406 | |
| Briviact ブリィビアクト | Brivaracetam | UCB Japan Co., Ltd. | H1 Completed | 2024-08-07 | 2026-04-08 | 609 | ≥10M yen/QALY | -4.29% -4.29 to -4.28% | 2026-08-01 | C2H2405 |
| Vyloy* ビロイ | Zolbetuximab | Astellas Pharma Inc. | H1 Completed | 2024-05-15 | 2025-10-15 | 518 | Cost increase (no added benefit); ≥15M yen/QALY | -4.29% | 2026-02-01 | C2H2404 |
| Elrexfio* エルレフィオ | Elranatamab | Pfizer Japan Inc. | H1 Completed | 2024-05-15 | 2025-11-14 | 548 | 2M–7.5M yen/QALY | 0% | C2H2403 | |
| Truqap* トルカプ | Capivasertib | AstraZeneca K.K. | H1 Completed | 2024-05-15 | 2025-12-10 | 574 | 11.25M–15M yen/QALY | -10.67% | 2026-06-01 | C2H2402 |
| Reblozyl* レブロジル | Luspatercept | Bristol-Myers Squibb K.K. | H1 Completed | 2024-04-10 | 2025-09-10 | 518 | Cost increase (no added benefit); ≥10M yen/QALY | -8.30% | 2026-02-01 | C2H2401 |
| LEQEMBI レケンビ | Lecanemab | Eisai Co., Ltd. | H1 Completed | 2023-12-13 | 2025-07-09 | 574 | ≥10M yen/QALY | -15.00% | 2025-11-01 | C2H2308 |
| EPKINLY* エプキンリ | Epcoritamab | Genmab K.K. | H1 Completed | 2023-11-15 | 2025-04-23 | 525 | 7.5M–11.25M yen/QALY | -2.73% | 2025-08-01 | C2H2307 |
| Wegovy ウゴービ | Semaglutide | Novo Nordisk Pharma Ltd. | H1 Completed | 2023-11-15 | 2025-05-14 | 546 | ≥10M yen/QALY | -8.27% -8.30 to -7.30% | 2025-11-01 | C2H2306 |
| LEQVIO* レクビオ | Inclisiran sodium | Novartis Pharma K.K. | H1 Completed | 2023-11-15 | 2025-05-14 | 546 | 5M–7.5M yen/QALY; Cost increase (no added benefit) | -11.00% | 2025-11-01 | C2H2305 |
| PHOZEVEL* フォゼベル | Tenapanor hydrochloride | Kyowa Kirin Co., Ltd. | H1 Completed | 2023-11-15 | 2025-05-14 | 546 | 2M–5M yen/QALY; Cost increase (no added benefit) | -11.02% -11.02 to -10.99% | 2025-11-01 | C2H2304 |
| Litfulo* リットフーロ | Ritlecitinib tosilate | Pfizer Japan Inc. | H1 Completed | 2023-08-23 | 2025-01-29 | 525 | 2M–7.5M yen/QALY; Cost increase (no added benefit) | -3.76% | 2025-06-01 | C2H2303 |
| GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System* device ゴア®CTAG胸部大動脈 ステントグラフト システム | Thoracic Stent Graft | W. L. Gore & Associates G.K. | H2 Completed | 2023-07-05 | 2025-01-29 | 574 | Cost-saving (dominant) | 0% | C2H2302 | |
| Besremi* ベスレミ | Ropeginterferon Alfa-2b | PharmaEssentia Japan K.K. | H1 Completed | 2023-05-17 | 2024-10-09 | 511 | -8.30% | 2025-02-01 | C2H2301 | |
| XOCOVA ゾコーバ | Ensitrelvir fumaric acid | Shionogi & Co., Ltd. | H1 Completed | 2023-03-08 | 2024-10-09 | 581 | Cost increase (no added benefit) | -4.28% | 2025-02-01 | C2H2213 |
| Mounjaro* マンジャロ | Tirzepatide | Eli Lilly Japan K.K. | H1 Completed | 2023-03-08 | 2024-09-11 | 553 | 2M–5M yen/QALY | 0% | C2H2212 | |
| Paxlovid パキロビッド | Nirmatrelvir / ritonavir | Pfizer Japan Inc. | H1 Completed | 2023-03-08 | 2026-06-24 | 1204 | Cost increase (no added benefit) | -4.29% | 2026-11-01 | C2H2211 |
| Tezspire* テゼスパイア | Tezepelumab | AstraZeneca K.K. | H1 Completed | 2022-11-09 | 2024-06-12 | 581 | Cost increase (no added benefit); ≥10M yen/QALY | -4.08% -4.08 to -4.04% | 2024-11-01 | C2H2210 |
| Sotyktu ソーティクツ | Deucravacitinib | Bristol-Myers Squibb K.K. | H1 Completed | 2022-11-09 | 2024-04-24 | 532 | 5M–7.5M yen/QALY | -8.57% | 2024-08-01 | C2H2209 |
| Lagevrio* ラゲブリオ | Molnupiravir | MSD K.K. | H1 Completed | 2022-08-10 | 2024-03-13 | 581 | Cost increase (no added benefit) | -8.18% | 2024-07-01 | C2H2208 |
| Ondexxya* オンデキサ | Andexanet alfa | AstraZeneca K.K. | H2 Completed | 2022-05-18 | 2023-10-11 | 511 | 2M–5M yen/QALY; <2M yen/QALY | 0% | C2H2207 | |
| Kerendia ケレンディア | Finerenone | Bayer Yakuhin, Ltd. | H1 Completed | 2022-05-18 | 2024-03-13 | 665 | 5M–7.5M yen/QALY | -2.70% -2.74 to -2.70% | 2024-07-01 | C2H2206 |
| Dysval* ジスバル | Valbenazine tosilate | Mitsubishi Tanabe Pharma Corp. | H2 Completed | 2022-05-18 | 2023-10-11 | 511 | 5M–7.5M yen/QALY | -1.43% | 2024-02-01 | C2H2205 |
| Vyvgart* ウィフガート | Efgartigimod alfa | argenx Japan K.K. | H1 Completed | 2022-04-13 | 2023-10-11 | 546 | Cost increase (no added benefit); ≥15M yen/QALY | -7.75% | 2024-02-01 | C2H2204 |
| Bimzelx* ビンゼレックス | Bimekizumab | UCB Japan Co., Ltd. | H1 Completed | 2022-04-13 | 2023-09-13 | 518 | <2M yen/QALY | 0% | C2H2203 | |
| Pivlaz* ピヴラッツ | Clazosentan sodium | Idorsia Pharmaceuticals Japan Ltd. | H1 Completed | 2022-04-13 | 2023-09-13 | 518 | 2M–5M yen/QALY | 0% | C2H2202 | |
| Lyfnua* リフヌア | Gefapixant citrate | MSD K.K. | H1 Completed | 2022-04-13 | 2023-06-14 | 427 | ≥10M yen/QALY | -7.73% | 2023-11-01 | C2H2201 |
| Expedium Verse Fenestrated Screw system* device Expedium Verse Fenestrated Screwシステム | Screw for spinal fusion | Johnson & Johnson K.K. | H2 Completed | 2021-12-08 | 2023-06-14 | 553 | Cost increase (no added benefit) | -3.07% | 2023-11-01 | C2H2115 |
| Padcev* パドセブ | Enfortumab vedotin | Astellas Pharma Inc. | H1 Completed | 2021-11-17 | 2023-02-15 | 455 | ≥15M yen/QALY | -8.18% | 2023-06-01 | C2H2114 |
| Retevmo* レットヴィモ | Selpercatinib | Eli Lilly Japan K.K. | H1 Completed | 2021-11-17 | 2023-08-23 | 644 | 2M–7.5M yen/QALY; 7.5M–11.25M yen/QALY | -0.16% | 2024-02-01 | C2H2113 |
| Micra AV* device Micra AV | Transcatheter pacing systems | Medtronic Japan Co., Ltd. | H2 Completed | 2021-10-13 | 2023-06-14 | 609 | ≥10M yen/QALY | -8.55% | 2023-11-01 | C2H2112 |
| Veklury* ベクルリー | Remdesivir | Gilead Sciences K.K. | H1 Completed | 2021-08-04 | 2023-01-18 | 532 | <2M yen/QALY; Cost increase (no added benefit); ≥10M yen/QALY | -2.12% | 2023-06-01 | C2H2111 |
| Revestive* レベスティブ | Teduglutide | Takeda Pharmaceutical Co., Ltd. | H2 Completed | 2021-08-04 | 2023-01-18 | 532 | 7.5M–11.25M yen/QALY; ≥10M yen/QALY | -7.09% | 2023-06-01 | C2H2110 |
| Aimovig アイモビーグ | Erenumab | ン(株) | H5 H5 (follows lead product) | 2021-08-04 | follows lead product | -5.04% H5 of C2H2101 | 2023-06-01 | C2H2109 list only | ||
| Ajovy アジョビ | Fremanezumab | Otsuka Pharmaceutical Co., Ltd. | H5 H5 (follows lead product) | 2021-08-04 | follows lead product | -5.05% H5 of C2H2101 | 2023-06-01 | C2H2108 list only | ||
| Verquvo* ベリキューボ | Vericiguat | H5 H5 (follows lead product) | 2021-08-04 | follows lead product | not found | C2H2107 list only | ||||
| Breyanzi* ブレヤンジ | Lisocabtagene maraleucel | H5 H5 (follows lead product) | 2021-05-12 | follows lead product | not found | C2H2106 list only | ||||
| Arikayce* アリケイス | Amikacin sulfate | Insmed G.K. | H1 Completed | 2021-05-12 | 2022-12-14 | 581 | ≥10M yen/QALY | -9.36% | 2023-06-01 | C2H2105 |
| Darzquro* ダラキューロ | Daratumumab / vorhyaluronidase alfa | Janssen Pharmaceutical K.K. | H1 Completed | 2021-05-12 | 2023-02-15 | 644 | 2M–7.5M yen/QALY; Cost-saving (dominant) | 0% | C2H2104 | |
| Polivy* ポライビー | Polatuzumab vedotin | Chugai Pharmaceutical Co., Ltd. | H1 Completed | 2021-05-12 | 2022-11-09 | 546 | 2M–7.5M yen/QALY | 0% | C2H2103 | |
| Yescarta* イエスカルタ | Axicabtagene ciloleucel | H5 H5 (follows lead product) | 2021-04-14 | follows lead product | not found | C2H2102 list only | ||||
| Emgality エムガルティ | Galcanezumab | Eli Lilly Japan K.K. | H1 Completed | 2021-04-14 | 2023-01-18 | 644 | 2M–5M yen/QALY; 5M–7.5M yen/QALY; ≥10M yen/QALY | -5.05% | 2023-06-01 | C2H2101 |
| Trelegy200* テリルジー200 | Fluticasone, Umeclidinium, Vilanterol | H5 H5 (follows lead product) | 2021-02-10 | follows lead product | -0.55% H5 of C2H1901 | 2021-07-01 | C2H2008 list only | |||
| Rybelsus* リベルサス | Semaglutide | Novo Nordisk Pharma Ltd. | H1 Completed | 2020-11-11 | 2022-07-20 | 616 | Cost increase (no added benefit); Cost-saving (dominant) | -2.51% -2.55 to -2.51% | 2022-11-01 | C2H2007 |
| Enerzair* エナジア | Indacaterol, Glycopyrronium, Mometasone | スファーマ | H5 H5 (follows lead product) | 2020-08-19 | follows lead product | -0.55% -0.57 to -0.55% H5 of C2H1901 | 2021-07-01 | C2H2006 list only | ||
| Entresto* エンレスト | Sacubitril valsartan sodium hydrate | ファーマ(株) | H5 H5 (follows lead product) | 2020-08-19 | follows lead product | 0% H5 of C2H1906 | C2H2005 list only | |||
| Zolgensma* ゾルゲンスマ | Onasemnogene abeparvovec | H3 Analysis suspended | 2020-05-13 | n/a | C2H2004 | |||||
| Enhertu* エンハーツ | Trastuzumab deruxtecan | Daiichi Sankyo Co., Ltd. | H1 Completed | 2020-05-13 | 2022-03-23 | 679 | 11.25M–15M yen/QALY; 7.5M–11.25M yen/QALY; Cost increase (no added benefit) | -2.15% | 2022-07-01 | C2H2003 |
| Cabometyx* カボメティクス | Cabozantinib | Takeda Pharmaceutical Co., Ltd. | H1 Completed | 2020-05-13 | 2022-05-18 | 735 | 2M–7.5M yen/QALY; Cost-saving (dominant) | 0% | C2H2002 | |
| Noxafil* ノクサフィル | Posaconazole | MSD K.K. | H1 Completed | 2020-04-08 | 2021-11-10 | 581 | 7.5M–10M yen/QALY; <2M yen/QALY | -0.46% | 2022-02-01 | C2H2001 |
| Coralan* コララン | Ivabradine hydrochloride | Ono Pharmaceutical Co., Ltd. | H2 Completed | 2019-11-13 | 2021-05-26 | 560 | 2M–5M yen/QALY | 0% | C2H1906 | |
| Trintellix トリンテリックス | Vortioxetine hydrobromide | Takeda Pharmaceutical Co., Ltd. | H1 Completed | 2019-11-13 | 2021-05-26 | 560 | Cost increase (no added benefit) | -4.26% -4.30 to -4.26% | 2021-11-01 | C2H1905 |
| Breztri* ビレーズトリ | Budesonide, Glycopyrronium, Formoterol | H5 H5 (follows lead product) | 2019-08-28 | follows lead product | -0.55% H5 of C2H1901 | 2021-07-01 | C2H1904 list only | |||
| Ultomiris ユルトミリス | Ravulizumab | Alexion Pharma G.K. | H1 Completed | 2019-08-28 | 2021-04-14 | 595 | Cost increase (no added benefit) | -4.29% | 2021-08-01 | C2H1903 |
| Kymriah キムリア | Tisagenlecleucel | Novartis Pharma K.K. | H3 Completed | 2019-05-15 | 2021-03-24 | 679 | 11.25M–15M yen/QALY; 2M–7.5M yen/QALY; 7.5M–11.25M yen/QALY | -4.30% | 2021-07-01 | C2H1902 |
| Trelegy* テリルジー | Fluticasone, Umeclidinium, Vilanterol | GlaxoSmithKline K.K. | H1 Completed | 2019-05-15 | 2021-03-24 | 679 | <2M yen/QALY; Cost increase (no added benefit); Cost-saving (dominant); Unable to evaluate | -0.54% -0.55 to -0.54% | 2021-07-01 | C2H1901 |
Since April 2024 every new-drug pricing sheet states whether the product falls under HTA (“費用対効果評価への該当性：該当する(H1)”). We read 145 sheets from 16 listing rounds: H1 21, H2 2, H5 4, not applicable 116. Below: products designated at listing whose Chuikyo result is still to come, soonest first. The window is the Chuikyo listing meeting + the interquartile range of designation-to-result days in this tracker (532–606 days, median 556.5, n=50). Estimates, not official dates.
| Listed | Product (ingredient) | Company | Class | Peak sales forecast | Chuikyo result expected (est.) |
|---|---|---|---|---|---|
| 2025-04-16 | Imdelltra (tarlatamab) イムデトラ | Amgen K.K. | H1 | ¥24.7bn | 2026-09 – 2026-12 |
| 2025-08-14 | Airwin (sotatercept) エアウィン | MSD K.K. | H1 | ¥54.4bn | 2027-01 – 2027-04 |
| 2025-08-14 | Welireg (belzutifan) ウェリレグ | MSD K.K. | H1 | ¥40.4bn | 2027-01 – 2027-04 |
| 2025-08-14 | Talvey (talquetamab) タービー | Janssen Pharmaceutical K.K. | H1 | ¥25.6bn | 2027-01 – 2027-04 |
| 2025-10-22 | Yorvipath (palopegteriparatide) ヨビパス | Teijin Pharma Limited | H1 | ¥12.9bn | 2027-03 – 2027-06 |
| subscribers only | |||||
| subscribers only | |||||
| subscribers only |
Showing 5 of 13 pending results. Peak sales = company forecast quoted in the Chuikyo pricing sheet.
Sources: C2H, National Institute of Public Health (c2h.niph.go.jp) and MHLW Chuikyo materials (Public Data License 1.0) — processed by Japan Pharma Regulatory Brief.
Used under the Public Data License 1.0 (compatible with CC BY 4.0) — processed, translated and analysed by Japan Pharma Regulatory Brief (unofficial). See the MHLW terms of use. This page is not made by, affiliated with or endorsed by MHLW, Chuikyo, the National Institute of Public Health or C2H. The Japanese originals prevail.
出典：「費用対効果評価 制度化以後に選定された品目」（国立保健医療科学院 保健医療経済評価研究センターホームページ）（https://c2h.niph.go.jp/results/item.html）、厚生労働省 中央社会保険医療協議会 総会の資料（医薬品等の費用対効果評価案について、費用対効果評価結果に基づく価格調整について）を加工して Japan Pharma Regulatory Brief が作成
Last built: .